Possibilities for assessing vasculogenic mimicry during the preclinical study of antitumor compounds

The dissemination activity of malignant neoplasms largely determines the prognosis in patients with tumors various localizations. Tumor growth depends on intensity formation new blood and alternative vessels. Vasculogenic mimicry (VM) differs from conventional neoangiovasculogenetic process involving vascular endothelium. VM is an type supply independent endothelial vessels, which refers to vessels lined tumor cells. Several methods are currently available for detecting vivo; however, immunohistochemical staining specific antigens remains gold standard. main criteria diagnosing structure have been identified. successful development anticancer therapy requires special attention preclinical study effect antitumor compounds process. Although mechanisms triggering be elucidated, strategy studying this at stage will contribute domestic antimetastatic drugs a multifactorial action.